KRYS vs. NBIS

Last updated Jun 9, 2026

KRYS (Krystal Biotech, Inc.) and NBIS (Nebius Group N.V.) are both stocks. KRYS operates in Biotechnology (Healthcare), while NBIS operates in Internet Content & Information (Communication Services). Over the past year, KRYS returned 120.36% vs 351.53% for NBIS. At a 0.14 correlation, their price movements are largely independent.

Performance

KRYS vs. NBIS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Krystal Biotech, Inc. (KRYS) and Nebius Group N.V. (NBIS). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, KRYS achieves a 22.40% return, which is significantly lower than NBIS's 160.44% return.

KRYS

• 1D: 0.25%
• 1M: -1.29%
• YTD: 22.40%
• 6M: 28.93%
• 1Y: 120.36%
• 3Y*: 32.77%
• 5Y*: 35.77%
• 10Y*: —

NBIS

• 1D: -4.31%
• 1M: 23.13%
• YTD: 160.44%
• 6M: 117.28%
• 1Y: 351.53%
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

KRYS vs. NBIS - Yearly Performance Comparison

	2026 (YTD)	2025	2024
KRYS Krystal Biotech, Inc.	22.40%	57.37%	-11.40%
NBIS Nebius Group N.V.	160.44%	202.18%	46.25%

Correlation

The correlation between KRYS and NBIS is 0.13, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.13
Correlation (All Time) Calculated using the full available price history since Oct 18, 2024	0.15

Fundamentals

Market Cap KRYS : $9.21B NBIS : $67.36B
EPS KRYS : $7.50 NBIS : $3.17
PE Ratio KRYS : 40.24 NBIS : 68.67
PEG Ratio KRYS : 0.10 NBIS : 23.59
PS Ratio KRYS : 21.70 NBIS : 65.42
PB Ratio KRYS : 7.21 NBIS : 9.30
Total Revenue (TTM) KRYS : $417.30M NBIS : $877.90M
Gross Profit (TTM) KRYS : $387.24M NBIS : $420.60M
EBITDA (TTM) KRYS : $185.45M NBIS : -$52.78M

Return for Risk

KRYS vs. NBIS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

KRYS

KRYS Risk / Return Rank: 94
KRYS Sharpe Ratio Rank: 96
KRYS Sortino Ratio Rank: 92
KRYS Omega Ratio Rank: 92
KRYS Calmar Ratio Rank: 96
KRYS Martin Ratio Rank: 96

NBIS

NBIS Risk / Return Rank: 94
NBIS Sharpe Ratio Rank: 96
NBIS Sortino Ratio Rank: 94
NBIS Omega Ratio Rank: 90
NBIS Calmar Ratio Rank: 96
NBIS Martin Ratio Rank: 95

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

KRYS vs. NBIS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Krystal Biotech, Inc. (KRYS) and Nebius Group N.V. (NBIS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	KRYS	NBIS	Difference
Sharpe ratio: Return per unit of total volatility	3.12	3.39	-0.27
Sortino ratio: Return per unit of downside risk	3.42	3.71	-0.28
Omega ratio: Gain probability vs. loss probability	1.47	1.41	+0.05
Calmar ratio: Return relative to maximum drawdown	7.59	7.79	-0.20
Martin ratio: Return relative to average drawdown	19.64	17.86	+1.78
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

KRYS vs. NBIS - Sharpe Ratio Comparison

The current KRYS Sharpe Ratio is 3.12, which is comparable to the NBIS Sharpe Ratio of 3.39. The chart below compares the historical Sharpe Ratios of KRYS and NBIS, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	KRYS	NBIS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	3.12	3.39	-0.27
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.47	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.63	3.19	-2.55

Drawdowns

KRYS vs. NBIS - Drawdown Comparison

The maximum KRYS drawdown since its inception was -53.42%, smaller than the maximum NBIS drawdown of -58.27%. Use the drawdown chart below to compare losses from any high point for KRYS and NBIS.

Drawdown Indicators

	KRYS	NBIS	Difference
Max Drawdown Largest peak-to-trough decline	-53.42%	-58.27%	+4.85%
Max Drawdown (1Y) Largest decline over 1 year	-15.94%	-45.47%	+29.53%
Max Drawdown (3Y) Largest decline over 3 years	-42.26%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-44.55%	—	—
Current Drawdown Current decline from peak	-4.60%	-17.58%	+12.98%
Average Drawdown Average peak-to-trough decline	-16.20%	-19.02%	+2.82%
Ulcer Index Depth and duration of drawdowns from previous peaks	6.15%	19.79%	-13.64%

Volatility

KRYS vs. NBIS - Volatility Comparison

The current volatility for Krystal Biotech, Inc. (KRYS) is 10.25%, while Nebius Group N.V. (NBIS) has a volatility of 33.60%. This indicates that KRYS experiences smaller price fluctuations and is considered to be less risky than NBIS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	KRYS	NBIS	Difference
Volatility (1M) Calculated over the trailing 1-month period	10.25%	33.60%	-23.35%
Volatility (6M) Calculated over the trailing 6-month period	27.29%	71.53%	-44.24%
Volatility (1Y) Calculated over the trailing 1-year period	38.91%	104.78%	-65.87%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	76.38%	110.72%	-34.34%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	74.19%	110.72%	-36.53%

Dividends

KRYS vs. NBIS - Dividend Comparison

Neither KRYS nor NBIS has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both KRYS and NBIS in my portfolio?

KRYS and NBIS have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, KRYS or NBIS?

NBIS has higher volatility (33.60%) compared to KRYS (10.25%). In terms of maximum drawdown, KRYS dropped -53.42% vs NBIS's -58.27%.

Which has better risk-adjusted returns?

NBIS currently has the higher Sharpe Ratio (3.39 vs 3.12), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.